Ionis Pharmaceuticals SG&A Expenses 2010-2024 | IONS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Ionis Pharmaceuticals sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Ionis Pharmaceuticals sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$74.8B
Chugai Pharmaceutical (CHGCY)	$70.2B
Takeda Pharmaceutical (TAK)	$41.1B
Sandoz Group AG (SDZNY)	$19.6B
Merck (MKKGY)	$18.8B
Astellas Pharma (ALPMY)	$17.3B
United Therapeutics (UTHR)	$16B
Neurocrine Biosciences (NBIX)	$14.5B
Summit Therapeutics (SMMT)	$14B
Shionogi (SGIOY)	$12.1B
Orion OYJ (ORINY)	$7.2B
Stevanato Group S.p.A (STVN)	$6.9B
Madrigal Pharmaceuticals (MDGL)	$6.4B
Corcept Therapeutics (CORT)	$5.8B
Hikma Pharmaceuticals Plc (HKMPF)	$5.5B
Grifols, S.A (GRFS)	$5B
Crinetics Pharmaceuticals (CRNX)	$3.5B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Recursion Pharmaceuticals (RXRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.2B
Soleno Therapeutics (SLNO)	$2B
Centessa Pharmaceuticals (CNTA)	$2B
Hypermarcas (HYPMY)	$1.9B
Indivior (INDV)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.5B
Evotec AG (EVO)	$1.5B
Dyne Therapeutics (DYN)	$1.4B
Xencor (XNCR)	$1.3B
Guardian Pharmacy Services (GRDN)	$1.3B